Trial Profile
A Response-Adapted Clinical Trial of Weekly Carfilzomib With or Without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Rituximab (Primary)
- Indications Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 08 Jan 2020 Status changed from completed to discontinued.
- 09 Jul 2019 Status changed from recruiting to completed.
- 26 Dec 2017 Status changed from not yet recruiting to recruiting.